ENG/中
老虎证券
行情
产品介绍
Cash Boost账户
新加坡股
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登录
立即注册
Toggle
美股
详情
本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务
卡利都斯软件
36.00
0.0000
成交量:
- -
成交额:
- -
市值:
23.93亿
市盈率:
-115.91
高:
36.00
开:
36.00
低:
36.00
收:
36.00
数据加载中...
总览
公司
新闻
公告
概念
没有相关数据
资金流向
资金流入:
资金流出:
实时
日
周
月
季度
年
新闻
全球最高价药物再次易主,天价基因疗法值不值?
21世纪经济报道
·
2022-11-26
全球最贵药物再次刷新!蓝鸟生物基因疗法获FDA批准,价格出炉
药融云
·
2022-09-20
蓝鸟生物公司(BLUE)盘前涨近20% 旗下SKYSONA获FDA加速批准用于治疗早期活性CALD
凤凰网港股
·
2022-09-19
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/CALD"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CALD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CALD\",,,,,undefined,":{"symbol":"CALD","market":"US","secType":"STK","nameCN":"卡利都斯软件","latestPrice":36,"timestamp":1523995200000,"preClose":36,"halted":3,"volume":0,"delay":0,"floatShares":54410000,"shares":66460419,"eps":-0.310592,"marketStatus":"停牌","change":0,"latestTime":"04-17 16:00:00 EDT","open":36,"high":36,"low":36,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.310592,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1753689600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1069304400000,"exchange":"NASDAQ","adjPreClose":36,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CALD\",,,,,undefined,":{"symbol":"CALD","floatShares":54410000,"roa":"--","roe":"--","lyrEps":0,"shares":66460419,"dividePrice":0,"high":36,"amplitude":0,"preClose":36,"low":36,"week52Low":19.255,"pbRate":"9.77","week52High":36.25,"institutionHeld":1.004,"latestPrice":36,"eps":-0.310592,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.310592,"open":36,"prevYearClose":36},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CALD\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CALD\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2286132187","title":"全球最高价药物再次易主,天价基因疗法值不值?","url":"https://stock-news.laohu8.com/highlight/detail?id=2286132187","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2286132187?lang=zh_cn&edition=fundamental","pubTime":"2022-11-26 17:33","pubTimestamp":1669455180,"startTime":"0","endTime":"0","summary":"基因疗法可引入功能基因来替代突变基因,以纠正或补偿缺陷和异常基因引起的疾病。 21世纪经济报道记者 魏笑 深圳报道 11月22日,美国FDA宣布澳大利亚制药公司CSL Behring的治疗B型血友病的一次性基因疗法Hemgenix获批,定价为350万美元,刷新了世界上最昂贵治疗方法的记录。 在不到半年的时间里,“全球最贵药物”已三易其主。 值得注意的是,这几款药物均为基因治疗产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/world/gjcj/2022-11-26/doc-imqmmthc6096666.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/world/gjcj/2022-11-26/doc-imqmmthc6096666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CALD","AAV"],"gpt_icon":0},{"id":"2269718295","title":"全球最贵药物再次刷新!蓝鸟生物基因疗法获FDA批准,价格出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2269718295","media":"药融云","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2269718295?lang=zh_cn&edition=fundamental","pubTime":"2022-09-20 14:49","pubTimestamp":1663656598,"startTime":"0","endTime":"0","summary":"据药融云数据显示,蓝鸟生物该基因疗法最早于2021年7月16日首次全球面世,上市国家包括欧盟、挪威、冰岛等国家,获批适应症为肾上腺脑白质营养不良。蓝鸟生物目前拥有约300名员工,比1月底减少了42%。蓝鸟生物预计其现金和短期收入将在2024年上半年为公司带来收益。目前该公司对镰状细胞疾病的基因治疗处于临床研究阶段,没有得到美国FDA的批准,安全性和疗效尚未确定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://k.sina.cn/article_3932040000_ea5e2b40001010t8x.html","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://k.sina.cn/article_3932040000_ea5e2b40001010t8x.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["CALD"],"gpt_icon":0},{"id":"2268996322","title":"蓝鸟生物公司(BLUE)盘前涨近20% 旗下SKYSONA获FDA加速批准用于治疗早期活性CALD","url":"https://stock-news.laohu8.com/highlight/detail?id=2268996322","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2268996322?lang=zh_cn&edition=fundamental","pubTime":"2022-09-19 16:27","pubTimestamp":1663576058,"startTime":"0","endTime":"0","summary":"蓝鸟生物公司盘前涨近20%,报7.56美元。蓝鸟生物宣布,美国食品和药物管理局已批准SKYSONA,也被称为elicel,用于减缓4-17岁早期活跃性脑肾上腺脑白质营养不良男孩神经功能障碍的进展。作为SKYSONA加速批准的条件之一,蓝鸟同意向FDA提供确认性的长期临床数据。蓝鸟将美国SKYSONA的批发收购成本定为300万美元。SKYSONA生物制剂许可证申请被美国FDA优先审查,蓝鸟在批准后获得了罕见的儿科优先审查凭证。SKYSONA此前被授予孤儿药、罕见儿科疾病和突破性治疗称号。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=e4472459a5bedd3ce65e0d6c75962e4f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","BK4139","BK4556","CALD","BLUE"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CALD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2018-02-08","symbol":"CALD","fiscalQuarterEnding":"2017/12","expectedEps":0.11,"name":null,"time":"盘后","type":"earning","dateTimestamp":1518066000000,"reportTimeType":"post","actualEps":0.09},{"market":"US","date":"2017-11-02","symbol":"CALD","fiscalQuarterEnding":"2017/09","expectedEps":-0.05,"name":null,"time":"盘后","type":"earning","dateTimestamp":1509595200000,"reportTimeType":"post","actualEps":-0.02},{"market":"US","date":"2017-08-03","symbol":"CALD","fiscalQuarterEnding":"2017/06","expectedEps":-0.07,"name":null,"time":"盘后","type":"earning","dateTimestamp":1501732800000,"reportTimeType":"post","actualEps":-0.07},{"market":"US","date":"2017-05-04","symbol":"CALD","fiscalQuarterEnding":"2017/03","expectedEps":-0.07,"name":null,"time":"盘后","type":"earning","dateTimestamp":1493870400000,"reportTimeType":"post","actualEps":-0.07},{"market":"US","date":"2017-02-07","symbol":"CALD","fiscalQuarterEnding":"2016/12","expectedEps":-0.04,"name":null,"time":"盘后","type":"earning","dateTimestamp":1486443600000,"reportTimeType":"post","actualEps":-0.06}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CALD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CALD\",market:\"US\",delay:false,,,undefined,":{}}}